Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Citation: ResearchGate
42 RheeN
[15] In August 2024, the SURMOUNT-1 three-year study (176-week treatment period) found that tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
Both products are available in our catalog, both are widely studied in the anti-aging research space, and both have distinct advantages depending on the research protocol
Tirzepatide functions as a dual incretin receptor agonist, binding both GIP and GLP-1 receptors with high affinity
US$ 26.83
US$ 23.72
US$ 24.32
US$ 27.28
US$ 24.44
